

Faculty Bio



Paul Edison, MD, PhD, FRCP
Professor of Neuroscience
Department of Brain Sciences
Imperial College London
London, UK

Paul Edison, MD, PhD, is a professor of neuroscience and clinical professor in the Department of Brain Sciences at Imperial College London in England as well as an honorary professor at Cardiff University in Wales. He is the editor-in-chief of the journal *Brain Connectivity*, an associate editor for the *Journal of Alzheimer's Disease*, and serves on the editorial boards of the *Journal of Neuroimaging* and *Contrast Media & Molecular Imaging*. He is also a consultant at Hammersmith Hospital in London.

He earned his Master of Philosophy and PhD at Imperial College London after becoming a clinician. He completed his higher training in the London Deanery and obtained his Certificate of Completion of Training (CCT) from the Postgraduate Medical Education and Training Board. He then became a Fellow of the Royal College of Physicians of Ireland and a Fellow of the Royal College of Physicians of the UK. He has received the prestigious Medical Research Council (MRC) Clinical Research Fellowship Award, the Higher Education Funding Council for England (HEFCE) Clinical Senior Lectureship Award, and various research scholarships.

Dr. Edison's research centers on neuroimaging with novel molecular probes. He has extensive experience with PET and MRI techniques for imaging pathophysiological changes associated with Alzheimer's disease, Parkinson's disease, and other neurodegenerative and neuroinflammatory conditions. His initial work evaluated one of the first amyloid imaging agents in Alzheimer's disease at the MRC Cyclotron Unit, Imperial College London, Hammersmith Hospital, and he has published seminal papers in the field. Since then, combined with his clinical expertise in degenerative diseases and dementia, he has investigated the relationship between amyloid deposition, microglial activation, glucose metabolism, and MRI changes in several disorders; he has further studied a range of transporters in the brain.

His current work focuses on the interplay between inflammation and immunity in neurodegenerative and neuroinflammatory disease, and how these relate to genetic information. He evaluates methods of modulating inflammation and amyloid in Alzheimer's disease as well as the influence of cardiometabolic factors on the development of neurodegenerative diseases by means of clinical and pre-clinical studies. He is the chief investigator for several multicentre studies testing novel therapies for neurodegenerative diseases, including evaluation of liraglutide in the treatment of Alzheimer's disease. He leads the Imperial College Memory Research Centre, is the chief investigator of several other imaging studies using PET and MRI, and runs a memory clinic at Imperial College Healthcare NHS Trust.

Dr. Edison has published in high impact journals such as *Brain*, *Annals of Neurology*, and *Neurology*. He has received grants from the MRC, the National Institute for Health and Care Research (NIHR)/HEFCE, Alzheimer's Society, Alzheimer's Research UK, Alzheimer's Drug Discovery Foundation US, and other funders. He collaborates closely with Novo Nordisk, GE Healthcare, Novartis, Piramal Life Sciences, and AstraZeneca. He has also received several international best paper awards.